Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROstate-specific Membrane Antigen DosImetry-Guided EndoradiotherapY: a Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy (PRODIGY-1)

NCT05896371 is registered in ClinicalTrials.gov with CHU de Quebec-Universite Laval as lead sponsor.

NCT NCT05896371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05896371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROstate-specific Membrane Antigen DosImetry-Guided EndoradiotherapY: a Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy (PRODIGY-1)
Lead sponsor
CHU de Quebec-Universite Laval
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
March 31, 2028
Completion date
March 31, 2034
Enrollment
500 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, metastatic cancer, metastatic prostate cancer, prostate cancer